Regulation and reprogramming of alternative splicing in cellular transformation

Projektinformationen

SPLICANCER

ID Finanzhilfevereinbarung: 752553

DOI 10.3030/752553

Abgeschlossenes Projekt

EK-Unterschriftsdatum 17 März 2017

Startdatum 1 Juli 2017

Enddatum 30 Juni 2019

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten € 168 277,20

EU-Beitrag € 168 277,20

Koordiniert durch

IFOM-ISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS
Italy

Ziel

Alternative splicing (AS), by affecting nearly 90 percent of human genes, is the major contributor to protein diversity. Mutations that disrupt AS regulatory sequences are a widespread source of human diseases. Various evidences suggest that an AS reprogramming is critical in cell adaptation during cancer development. In spite of increasing interest in the potential oncogenic role of AS, little is known about the molecular mechanisms behind its deregulation during the somatic to the cancer cell transformation.
Our aim is to contribute to the characterisation of AS reprogramming during the somatic to the proliferative cancer cell transformation using myosin VI as model system. Recent studies from the host lab reported how myosin VI AS modulates its interactome leading to different cellular functions (endocytosis for the long isoform and cell migration for the short one). The lab found that alternative myosin VI splicing is aberrantly regulated in cancer, where exon skipping dictates cell addiction to myosin VIshort for tumour cell migration.In this proposal, we intends to 1) Identify the myosin VI’s alternative splicing regulators and define their role in vitro, 2) identify common splicing-regulated events that occur during the establishment of a fully polarized epithelial architecture and that are possibly deregulated in cancer (AS reprogramming), 3) assess whether cancer stem cells express a specific set of the identified AS genes.Preliminary results revealed that myosin VI isoforms expression can be switch on/off in selective culture conditions. We will take advantage of this beahviour to set up our analysis based on a multidisciplinary approach that includes biochemical, mass spectrometry and cellular biological assayes. The new set of information will gained with this proposal will be instrumental to understanding the molecular mechanism at the basis of AS (de)regulation for myosin VI and more in general for cell transformation during cancer progression.

Wissenschaftliches Gebiet

• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › medical biotechnology › cells technologies › stem cells
• medical and health sciences › clinical medicine › oncology
• social sciences › political sciences › political policies › civil society
• natural sciences › biological sciences › genetics › genomes

Programm/Programme

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Thema/Themen

• MSCA-IF-2016 - Individual Fellowships

Aufforderung zur Vorschlagseinreichung

H2020-MSCA-IF-2016

Finanzierungsplan

MSCA-IF-EF-ST - Standard EF

Koordinator

IFOM-ISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS

• Netto-EU-Beitrag: € 168 277,20
• Adresse: VIA ADAMELLO 16 ; 20139 Milano ; Italien
• Region: Nord-Ovest › Lombardia › Milano
• Aktivitätstyp: Research Organisations
• Gesamtkosten: € 168 277,20